Clinical Trial Update: REBYOTA™ Prospective Registry

View source ↗

Summary

A prospective registry update for REBYOTA evaluating its use to prevent recurrence of Clostridioides difficile infection has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection

Drugs mentioned

• REBYOTA (fecal microbiota product)

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Recurrence of Clostridium Difficile Infection | Status: COMPLETED